Denali Therapeutics price to free cash flow DNLI

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 11.2×; Feb 2022
8-year median: 16.0×
8-year range: 10.9× to 56.9×
Peer median: 27.9×

Denali Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Feb 2022, at 11.2×.

On the days it had one over the last 8 years, its median was 16.0×, from 10.9× in Jan 2022 to 56.9× in Apr 2019.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	11.2×	10.9×	14.0×
2021	15.1×	13.7×	22.5×
2020	n/m a value too high to mean anything
2019	50.2×	39.7×	56.9×

Against its peers

Companies in Biotechnology nearest Denali Therapeutics' size, closest first, today.

Company	Price to free cash flow
DNLIDenali Therapeutics	n/m
ADMAAdma Biologics	20.5×
VCELVericel	35.3×
KRYSKrystal Biotech	35.8×
MGTXMeiraGTx	84.5×
RGENRepligen	89.2×
TECHBIO-TECHNE	43.2×
HALOHalozyme Therapeutics	17.7×
NBIXNeurocrine Biosciences	16.7×
EXELExelixis	13.6×
INCYIncyte	12.2×
Peer median	27.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Denali Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.